AVDL News and Press, Avadel Pharmaceuticals plc From 02/07/24

DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Oppenheimer 34 th Annual Health...

2024-01-29 15:17:00 ET Summary Jazz Pharmaceuticals is likely to fall short of its 2025 revenue goal of $5 billion unless it makes a bold M&A move. Despite this, the stock looks undervalued and has the potential to re-rate higher, driven by the growth of Xywav, Rylaze, and Epi...

2024-01-28 02:56:55 ET Summary Avadel Pharmaceuticals has made good progress with the launch of Lumryz, enrolling 1,900 patients and generating $19 million in Q4 net sales. Legal risks from competitor Jazz Pharmaceuticals remain a concern, with ongoing litigation and the potential...

2024-01-26 14:15:33 ET Summary Alkermes plc, a neuroscience company, has undergone restructuring and simplification, including spinning out its oncology business and selling its manufacturing facility. Despite a turbulent year, Alkermes' stock price remains relatively stable, but ...

2024-01-11 11:31:29 ET Summary Avadel Pharma's launch of its product LUMRYZ is expected to drive the company's stock performance. LUMRYZ appears to have momentum and is differentiated from current narcolepsy treatments. The potential revenue for Avadel from LUMRYZ could ultima...

2024-01-08 13:31:27 ET More on Avadel Pharmaceuticals Avadel: Lumryz Lights Up The Oxybate Market, Maintaining Buy Rating Assessing Avadel's Lumryz: Clinical Innovation Versus Economic Realities Avadel Pharmaceuticals PLC (AVDL) Q3 2023 Earnings Call Transcript ...

-- Approximately $19 million and $28 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter and full year 2023, respectively -- -- Generated continued robust demand for LUMRYZ with greater than 1,900 patients enrolled in RYZUP TM and more than 1...

2023-11-27 13:44:41 ET More on Jazz Pharmaceuticals Jazz Pharmaceuticals PLC (JAZZ) Q3 2023 Earnings Call Transcript Jazz Pharmaceuticals plc 2023 Q3 - Results - Earnings Call Presentation Jazz Pharma: Playing The High Notes With Xywav Jazz Pharma enters coll...

2023-11-23 04:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-14 16:00:00 ET Summary Avadel Pharmaceuticals reported strong Q3 earnings for Lumryz, exceeding consensus estimates and demonstrating successful market launch. Avadel's strategic market positioning and focus on high-volume prescribers contribute to its strong market positi...